These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37775345)

  • 21. ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor.
    Benenati S; Gragnano F; Scalamera R; De Sio V; Capolongo A; Cesaro A; Annibali G; Campagnuolo S; Silverio A; Bellino M; Centore M; Schettino M; Bertero E; Caretta G; Rezzaghi M; Veneziano F; De Nardo D; De Rosa G; De Luca L; Galasso G; Menozzi A; Musumeci G; Cirillo P; Calabrò P; Porto I
    Int J Cardiol; 2024 Dec; 417():132568. PubMed ID: 39284439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y
    Abtan J; Ducrocq G; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL
    Circ Cardiovasc Interv; 2019 Mar; 12(3):e007445. PubMed ID: 30871355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-thrombotic Therapy With Cangrelor and Bivalirudin in Venoarterial Extracorporeal Membrane Oxygenation Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Experience.
    Baldetti L; Nardelli P; Ajello S; Melisurgo G; Calabrò MG; Pieri M; Scandroglio AM
    ASAIO J; 2023 Jul; 69(7):e346-e350. PubMed ID: 36490373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
    Waite LH; Phan YL; Spinler SA
    Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
    Angiolillo DJ; Firstenberg MS; Price MJ; Tummala PE; Hutyra M; Welsby IJ; Voeltz MD; Chandna H; Ramaiah C; Brtko M; Cannon L; Dyke C; Liu T; Montalescot G; Manoukian SV; Prats J; Topol EJ;
    JAMA; 2012 Jan; 307(3):265-74. PubMed ID: 22253393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    White HD; Bhatt DL; Gibson CM; Hamm CW; Mahaffey KW; Price MJ; Steg PG; Stone GW; Cortese B; Wilensky M; Deliargyris EN; Liu T; Prats J; Harrington RA
    JACC Cardiovasc Interv; 2015 Mar; 8(3):424-433. PubMed ID: 25703887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cangrelor Use Patterns and Transition to Oral P2Y
    Rymer JA; Bhatt DL; Angiolillo DJ; Diaz M; Garratt KN; Waksman R; Edwards L; Tasissa G; Salahuddin K; El-Sabae H; Dell'Anna C; Davidson-Ray L; Washam JB; Ohman EM; Wang TY
    J Am Heart Assoc; 2022 Jun; 11(11):e024513. PubMed ID: 35621210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
    Droppa M; Borst O; Rath D; Müller K; Gawaz M; Bhatt DL; Geisler T
    Cell Physiol Biochem; 2017; 42(4):1336-1341. PubMed ID: 28700987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cangrelor: A Review in Percutaneous Coronary Intervention.
    Keating GM
    Drugs; 2015 Aug; 75(12):1425-34. PubMed ID: 26201463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What is the Role of Cangrelor in Patients Undergoing PCI?
    Droppa M; Geisler T
    Curr Vasc Pharmacol; 2018; 16(5):484-489. PubMed ID: 29345586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives.
    De Luca L; Steg PG; Bhatt DL; Capodanno D; Angiolillo DJ
    J Am Heart Assoc; 2021 Jul; 10(13):e022125. PubMed ID: 34212768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cangrelor PK/PD analysis in post-operative neonatal cardiac patients at risk for thrombosis.
    Vargas D; Zhou H; Yu X; Diamond S; Yeh J; Allada V; Krishnamurthy G; Price M; Allen B; Alexander J; Schmidhofer J; Kreutzer J; Vincent J; Morell V; Bacha E; Diacovo T
    J Thromb Haemost; 2021 Jan; 19(1):202-211. PubMed ID: 33078501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
    Groves EM; Bhatt DL; Steg PG; Deliargyris EN; Stone GW; Gibson CM; Hamm CW; Mahaffey KW; White HD; Angiolillo DJ; Prats J; Harrington RA; Price MJ
    Circ Cardiovasc Interv; 2018 Apr; 11(4):e005635. PubMed ID: 29632238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survivors of out-of-hospital cardiac arrest treated with percutaneous coronary intervention: Thrombotic and bleeding events among different oral P2Y
    Picard F; Laghlam D; Diefenbronn M; Seret G; Varenne O; Dumas F; Cariou A
    Arch Cardiovasc Dis; 2021; 114(8-9):577-587. PubMed ID: 34257048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perioperative Antiplatelet Bridging With Cangrelor: A Cohort Study and Narrative Review.
    Salgia A; Krueger CK; Gillette MA
    Ann Pharmacother; 2023 May; 57(5):544-552. PubMed ID: 36004393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
    Alexopoulos D; Pappas C; Sfantou D; Lekakis J
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):13-22. PubMed ID: 29228817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Cangrelor as Adjunct Therapy to Percutaneous Coronary Intervention.
    Hideo-Kajita A; Rogers T; Buchanan K; Iantorno M; Gajanana D; Ozaki Y; Dan K; Kolm P; Brathwaite E; Beyene S; Melaku G; Meirovich Y; Dheendsa A; Garcia-Garcia HM; Torguson R; Waksman R
    Am J Cardiol; 2019 Apr; 123(8):1228-1238. PubMed ID: 30738570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.